Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis

29 de julio de 2019 actualizado por: Medtronic - MITG
To evaluate the ability of the PillCam® Colon Capsule Endoscope to detect and classify Ulcerative colitis

Descripción general del estudio

Estado

Terminado

Descripción detallada

Ulcerative colitis (UC) is a disorder of unknown origin that may be characterized by acute and chronic inflammation of the colon. The extent of the colonic mucosal inflammation varies among individuals, but the disease almost always involves the rectum. Ulcerative colitis has required evaluation by colonoscopy to determine the extent and severity of the disease. The PillCam platform offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the PillCam platform include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the PillCam platform may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon.

The PillCam® SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 700,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. Further details of the PillCam® Colon Capsule Endoscope (PCCE) can be found in the device description section.

In previous studies, the PillCam colon platform has been shown to be safe and to be able to demonstrate colon polyps and cancers. This study is an extension to a trial evaluating the use of PCCE in ulcerative colitis that has already been completed in Hong Kong (n=40). This study is designed to assess the ability of the capsule to accurately detect inflammatory lesions and thus classifying the extent and severity of disease in subjects with ulcerative colitis in comparison to traditional colonoscopy.

Tipo de estudio

De observación

Inscripción (Actual)

97

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Hong Kong, Hong Kong
        • Chinese university of Hong Kong, Princes of Walses Hospital
      • Singapore, Singapur, 119074
        • Department of Medicine, National University Hospital
      • Taipei, Taiwán
        • Department of Internal Medicine & Health Management Center, National Taiwan University Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease

The study population will consist of subjects who fulfill all the inclusion criteria and none of the exclusion criteria.

Descripción

Inclusion Criteria:

  • Subjects 18-70
  • Suspected or known ulcerative colitis patients

Exclusion Criteria:

  • Subject has dysphagia
  • Subject has congestive heart failure
  • Subject who can not tolerate bowel preparation
  • Poor bowel preparation
  • Subject has renal insufficiency
  • Subject is known or is suspected to suffer from intestinal obstruction.
  • Subject has a cardiac pacemaker or other implanted electro-medical devices.
  • Subject is pregnant
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Subject suffers from life threatening conditions
  • Subject is currently participating in another clinical study
  • Subject has constipation (less than 3 bowel movements/week)
  • Subject has known slow gastric emptying time

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
A
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Agreement level between capsule and colonoscopy in classifying colitis into the above (see section 3.1) categories.
Periodo de tiempo: within 7 days
within 7 days

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Number, type and severity of adverse events with both PCCE and standard colonoscopy
Periodo de tiempo: Within 7 days
Within 7 days
Accuracy parameters for detecting active UC
Periodo de tiempo: within 7 days
within 7 days
Disease severity scoring index for both PCCE and .standard colonoscopy
Periodo de tiempo: within 7 days
within 7 days
Colon cleansing level score for both PCCE and standard colonoscopy.
Periodo de tiempo: within 7 days
within 7 days
Grading of the bubbles interference at the colon for PCCE.
Periodo de tiempo: Within 7 days
Within 7 days
Percentage of excreted colon capsules
Periodo de tiempo: Within 7 Days
Within 7 Days
PCCE transit time from ingestion to excretion and colon transit time
Periodo de tiempo: Within 7 Days
Within 7 Days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Josef Sung, Prof., Chinese University of Hong Kong

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de abril de 2007

Finalización primaria (Actual)

1 de febrero de 2010

Finalización del estudio (Actual)

1 de marzo de 2010

Fechas de registro del estudio

Enviado por primera vez

24 de enero de 2008

Primero enviado que cumplió con los criterios de control de calidad

29 de enero de 2008

Publicado por primera vez (Estimar)

30 de enero de 2008

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

31 de julio de 2019

Última actualización enviada que cumplió con los criterios de control de calidad

29 de julio de 2019

Última verificación

1 de marzo de 2010

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir